A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Trial Profile

A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Bupivacaine (Primary) ; Bupivacaine/meloxicam (Primary) ; Bupivacaine/meloxicam (Primary) ; Meloxicam (Primary)
  • Indications Perioperative pain
  • Focus Therapeutic Use
  • Sponsors Heron Therapeutics
  • Most Recent Events

    • 26 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 31 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Dec 2016 This trial is now studying Bupivacaine and meloxicam alone along with combination of the same. Thus changes in official title, purpose and treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top